ZandCell Appoints Chief Medical Officer to Accelerate the Execution of International Medical Development Strategies
ZandCell Appoints Chief Medical Officer to Accelerate the Execution of International Medical Development Strategies
Stockholm, SWEDEN, March 03, 2020 – ZandCell AB. (“ZandCell” or the “Company”), a biotechnology company focused on the development of therapies for untreatable diseases, is pleased to announce that Professor Doctor Panos Zavos has been appointed the Company’s Chief and Director of the medical operations.
Professor Zavos brings a unique blend of medical expertise across multiple areas including clinical medicine, fundamental & basic research in advance therapeutics and management consulting.
“The potential to generation of new therapies is limitless and it is our goal to continue expanding the scope of new clinical applications for our community of hospitals and medical professionals worldwide,” affirmed Michael Zand, CEO, and founder of ZandCell. “Professor Zavos’ background and track record across different sectors of life sciences, including biopharma, will help the execution of new clinical-grade applications. In turn, this will allow the longitudinal expansion of treatment for patients through multi-level scientific approaches and the optimization of treatment development at an accelerated fashion.”
About Professor Zavos
Professor Zavos is recognized worldwide as the “Father of Andrology” and a leading researcher and a strong authority in the areas of male reproductive medicine, gamete physiology, male infertility, Andrology and other ART procedures including the development of in-vitro round spermatid manipulations (ROSI). Dr. Zavos is also recognized as an international authority on cloning, SCNT and embryonic stem cells, pioneering the creation of the first cloned embryos and transferring them in women for reproductive purposes. He is also known for his pioneering work on many other aspects of reproductive medicine and smoking and its effects on human reproductive performance.
About ZandCell
ZandCell is a privately held, biotechnology company committed to bringing to market life-transforming therapeutics for patients with untreatable diseases. The company focuses on diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no current effective treatment modalities.
The company is led by a management team experienced in the development and commercialization of disease therapeutics. ZandCell’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. The overall objective of ZandCell and its operations is to develop medical treatments in the fields of regenerative medicine, gene editing, and immunotherapy worldwide.
For more information on ZandCell email: info@ZandCell.com.
Please visit the company’s website at ZandCell.com or follow @ZandCell on Twitter.
